CHAPEL HILL – UNC Lineberger Comprehensive Cancer Center has received $40 million from the OpenAI Foundation for an initiative using clinical data and artificial intelligence to improve personalized cancer vaccines.
The UNC School of Medicine announced the grant Sept. 15. The program is led by Alex Rubinsteyn, PhD, and Benjamin Vincent, MD, and will combine laboratory measurements, clinical information and computational tools to study how patients’ immune systems respond to cancer vaccines.
The research team plans to analyze hundreds of de-identified tumor and immune-system samples drawn from three biobanks. UNC said the work will include clinical trials comparing multiple vaccine formulations in patients with triple-negative breast cancer.
The OpenAI Foundation described the UNC effort as the Initiative for Generative Immunotherapy. It said the project will create public multimodal datasets covering hundreds of tumors across multiple cancer types, including measurements of tumor-cell surface proteins and patient T-cell responses.
The foundation said the data will be made broadly accessible with privacy and consent protections. UNC said findings and datasets from the work will be shared to help researchers evaluate which vaccine approaches generate stronger immune responses.
The $40 million award is part of the foundation’s Public Data for Health program, which announced an initial group of more than $125 million in grants to universities and nonprofit organizations. The UNC award represents research funding, not a commercial investment or a guarantee that a vaccine will reach the market.
UNC Lineberger is based in Chapel Hill and is North Carolina’s only public National Cancer Institute-designated Comprehensive Cancer Center. The current milestone is the grant and launch of the research initiative; trial results and clinical outcomes have not been reported.
